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Abstract
Inhaled corticosteroids (ICS) reduce COPD exacerbation frequency and slow decline in health related quality of life
but have little effect on lung function, do not reduce mortality, and increase the risk of pneumonia. We
systematically reviewed trials in which ICS have been withdrawn from patients with COPD, with the aim of
determining the effect of withdrawal, understanding the differing results between trials, and making
recommendations for improving methodology in future trials where medication is withdrawn. Trials were identified
by two independent reviewers using MEDLINE, EMBASE and CINAHL, citations of identified studies were checked,
and experts contacted to identify further studies. Data extraction was completed independently by two reviewers.
The methodological quality of each trial was determined by assessing possible sources of systematic bias as
recommended by the Cochrane collaboration. We included four trials; the quality of three was adequate. In all
trials, outcomes were generally worse for patients who had had ICS withdrawn, but differences between outcomes
for these patients and patients who continued with medication were mostly small and not statistically significant.
Due to data paucity we performed only one meta-analysis; this indicated that patients who had had medication
withdrawn were 1.11 (95% CI 0.84 to 1.46) times more likely to have an exacerbation in the following year, but the
definition of exacerbations was not consistent between the three trials, and the impact of withdrawal was smaller
in recent trials which were also trials conducted under conditions that reflected routine practice. There is no
evidence from this review that withdrawing ICS in routine practice results in important deterioration in patient
outcomes. Furthermore, the extent of increase in exacerbations depends on the way exacerbations are defined and
managed and may depend on the use of other medication. In trials where medication is withdrawn, investigators
should report other medication use, definitions of exacerbations and management of patients clearly. Intention to
treat analyses should be used and interpreted appropriately.
Review
Introduction
The mortality, morbidity and economic burden of
Chronic Obstructive Pulmonary Disease (COPD)
exacerbations is well documented [1-4]. Reduction in
the frequency of exacerbations is a major therapeutic
aim in COPD and treatment with inhaled corticoster-
oids (ICS) has been associated with a 25% reduction in
exacerbations [5]. In a Cochrane review by Yang, ICS
were found both to reduce the frequency of COPD
exacerbations by 0.26 per patient per year (weighted
mean difference: 95% CI -0.37 to -0.14) and to slow the
rate of decline in health related quality of life as deter-
mined by the St George’s Respiratory Questionnaire
(weighted mean difference: -1.22 units/year, 95% CI
-1.83 to -0.60) [6]. Despite this, Yang’s review failed to
demonstrate any effect of ICS on the decline in lung
function or on mortality, although a more recent paper
identifies a small clinically insignificant effect on lung
function [7]. It is now recognised that ICS in stable
COPD are associated with an increased risk of pneumo-
nia (relative risk 1.34 95% CI, 1.03-1.75) [8], and the
long-term use of high-dose ICS has been associated
with adverse effects including cataracts [9], glaucoma
[10] and osteoporosis [11]. UK National Institute of
Health and Clinical Excellence (NICE) guidance
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encourage their use with bronchodilators if patients
have moderate or severe COPD and are still sympto-
matic, or are experiencing two or more exacerbations
requiring treatment per year [3].
In light of the debate around the role of long term
ICS in COPD [8], consideration of the potential effects
of withdrawing ICS becomes important, but there are
no reviews of withdrawing treatment. The aims of this
systematic review were to determine the effects of with-
drawal of ICS, to use the review process to explore the
reasons for different results between trials, and to make
recommendations for improving methodology in future
trials where medication is withdrawn.
Method
Search strategy and selection criteria
The search strategy involved text words for COPD and
the names of inhaled steroids used in COPD and rele-
vant Medical Subject Headings (MeSH). Boolean logic
was used to truncate and combine terms and the search
strategy was modified several times before being finally
performed (full search available from the authors). The
Cochrane Library and the Database of Abstracts and
Reviews were searched for existing systematic reviews
on this topic. None were found so we searched for pub-
lished original articles in PubMed, EMBASE and
CINAHL from inception to February 2007. Criteria for
the inclusion and exclusion of studies were based on the
four facets: Population, Intervention, Comparison and
Outcome. Studies were included if they were rando-
mised controlled trials, comparing patients withdrawn
from ICS with those not withdrawn, in which the diag-
nostic criteria for COPD were consistent with GOLD,
NICE or ATS [1,3,12]. Studies were included if they
assessed any of the following outcome measures: lung
function, exacerbations, health related quality of life,
exercise tolerance and the use of healthcare facilities
because of respiratory symptoms. Due to time and
resource constraints it was not possible to include non-
English language papers.
Procedures
Two reviewers independently reviewed papers identified
by the electronic search for potential inclusion on the
basis of their titles and abstracts and independently
scrutinised full texts of papers considered potentially
includable to confirm inclusion/exclusion. Any discre-
pancies were resolved through discussion between the
two reviewers. To identify further studies, we searched
citations of included reports and contacted experts in
the field. Data from each included trial were extracted
independently by two reviewers. Again, disagreements
were resolved through discussion. We extracted data on
outcomes, the design and conduct of the trial, the way
in which exacerbations were defined, the protocol for
managing severe exacerbations, and the methodological
quality of the trials.
Trial quality
To assess quality we used the Cochrane collaboration
classification scheme for assessing bias [13]. We used
the following criteria: method of randomisation,
sequence generation, and allocation concealment for
selection bias; blinding for performance bias; whether
the loss of patients were accounted for and whether the
analysis was by intention to treat for attrition bias;
whether the outcome assessor was blinded for detection
bias, and whether there was evidence of selective report-
ing of outcome measures for reporting bias.
Analysis
We only conducted a meta-analysis on outcome data
from trials which we rated as acceptable in terms of bias
on at least three of the five bias criteria listed above, and
only when relevant data could be obtained from at least
three trials. For other outcomes we report results from
individual trials. We meta-analysed outcome data using
the random effects method of DerSimonian & Laird
[14], with the estimate of heterogeneity being taken
from the Mantel-Haenszel model and assessed for statis-
tical significance using a Cochran Q-test which follows a
chi-squared distribution. All statistical analyses were
performed in Stata, version 10.1. We identified features
of the included trials that we felt were important in
interpreting results. Based on an examination of the
treatment of these features in the included papers, we
make recommendations for the future design of these
types of trial. Statistical significance was reported at the
5% level in all trials and we report all results at that
level.
Results
The electronic search identified 107 publications of
which 103 were excluded on the basis of their titles and
a b s t r a c t s( F i g u r e1 ) .T h ef u l lt e x t so ff o u rp a p e r sw e r e
retrieved. One was excluded because it did not compare
patients withdrawn from ICS with those not withdrawn.
A further trial published during the course of this
research was included; one of the authors of the present
paper is an author on this trial. Searching through refer-
ences of these trials or contacting experts did not iden-
tify any further studies.
Characteristics of the included trials are shown in
Table 1 and characteristics of the patients included in
Table 2. The number of patients in these trials ranged
from 24-615. Three of the trials were parallel group
trials (COPE, COSMIC, WISP) [15-17] ranging in
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Page 2 of 10duration from 10-12 months with a run-in period of
between 2 weeks and 4 months. The reason for a run-in
is usually to screen patients so that those who are
unsuitable for the trial can be identified and excluded
before randomisation. In two of the trials, however, the
run-in period involved all patients being administered
the same inhaled corticosteroid treatment, and in the
COSMIC trial authors explain the length of their run-in,
which involved all patients being put on the same treat-
ment as ‘to be on the safe side of the GOLD guidelines
which recommend a trial period of 6 weeks to 3 months
to get a plateau in the response to FEV1 to ICS’.T h e
fourth trial was a cross-over trial with a total duration
of 12 weeks and no run-in period [18]. The parallel
trials used fluticasone as the inhaled steroid but the
cross-over trial used beclomethasone. During the run-in
period, WISP patients received their usual medication,
COSMIC and COPE patients were given the inhaled
steroid which was to be used for the remainder of the
trial.
The three parallel trials all had an acceptable level of
bias for three or more bias criteria (Table 3). The fourth
trial appeared to have a much greater potential for bias,
was substantially different in size and design, and had a
different active treatment. We did not consider data
from this trial for our meta-analyses. Thus we could
only meta-analyse data from a maximum of three trials.
For most of the outcomes we considered, data were
either not reported or not reported clearly for at least
one trial. As a result we only conducted a meta-analysis
f o ro n eo u t c o m e :w h e t h e ro rn o tap a t i e n th a da n
exacerbation during the study period.
Meta-analysis indicated that patients who had been
withdrawn from ICS were slightly more likely to experi-
ence an exacerbation in the study period (odds ratio
1.11, 95% CI 0.84 to 1.46), but the effect was not statis-
tically significant (Figure 2). Statistical heterogeneity was
n o tp r e s e n t( P - v a l u e=0 . 3 6 9 ) ,b u tw ef e l tt h a tc l i n i c a l
heterogeneity was. We outline this clinical heterogeneity,
and reasons that we had to be cautious about conduct-
ing this meta-analysis, in the discussion. Results relating
to exacerbations were reported in more than one way in
all three parallel trials. In these trials, patients who were
withdrawn had more exacerbations than those who were
PubMed 
EMBASE 
37 
4  
35 
35 
4 
31 excluded: 
17 are not withdrawal trials 
6 are about conditions other than COPD 
4 are about treatments other than inhaled 
    steroids 
1 is not in English 
1 is assessing the effect of patient withdrawal 
    from trials 
1 is not about the treatment of COPD 
1 is a trial protocol 
37 excluded: 
19 are about conditions other than COPD 
5 are not withdrawal trials 
5 are not about the treatment of COPD 
4 are about treatments other than inhaled 
    steroids 
4 are about optimising patient care in COPD 
31 excluded: 
16 are not withdrawal trials 
7 are about conditions other than COPD 
5 are about treatments other than inhaled 
    steroids 
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1 is assessing the effect of patient withdrawal 
    from trials 
1 is evaluating bias in non-randomised trials 
0 
4 
1  0 
4 
Total number of studies 
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(after removal of duplicate 
studies) 
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it is not a 
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1 excluded: 
it is not a 
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0 
3 
3 
CINAHL 
Stage 1 
Titles/abstracts 
Stage 2 
Full text 
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Citations 
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results 
Figure 1 Summary of the research process.
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Page 3 of 10not withdrawn. The difference was significant in COPE
[16] but not in WISP [15] or COSMIC [17] (Table 4).
In WISP, patients who were receiving placebo experi-
enced an exacerbation on average 19 days earlier than
those receiving inhaled steroid (median = 44 days (CI
29-59) v. 63 (CI 53-74) days, P = 0.05) [15]. The mean
difference in the COPE trial was 34.6 days (95% CI
15.4-53.8) [16]. Change in lung function from baseline
was worse in the placebo group in all four trials but
only in COSMIC was the difference statistically signifi-
cant (Table 4).
All three parallel trials [15-17] assessed health related
q u a l i t yo fl i f eb ym e a n so ft h eS tG e o r g e ’s Respiratory
Questionnaire (SGRQ) [19]. In COSMIC and WISP
[15,17] there was no significant difference in the total
SGRQ scores, whereas in COPE [16], patients in the pla-
cebo group experienced significantly poorer health sta-
tus in terms of overall score (Table 4). Only COPE and
O’Brien measured reported exercise tolerance and there
w a sn oe v i d e n c et h a tt h i sw a saffected by withdrawing
treatment. In COPE, the use of health care facilities was
greater in the placebo group.
Discussion
There is no conclusive evidence from the trials included in
our review that withdrawal of ICS has an effect on the
Table 1 Description of studies
Trial/
Country/
Publication
date
Type of
study
Duration & follow-
up
Number of
patients
randomised
Run-in period Trial period medication Outcomes
Duration Treatment Steroid group Withdrawn
group
WISP
14/
United
Kingdom/
2007
Parallel 12 months (follow up
every 3 months)
260 2 weeks Patient’s usual
medication
FP 500 ug twice
daily
Placebo Exacerbation
frequency*
Time to first
exacerbations
Respiratory
symptoms
PEFR
Reliever
inhaler use
Lung function
HRQL
O’Brien
17/
USA/2001
Crossover 12 weeks (follow up
every 3 weeks)
24 None n/a BDP 84 ug 4 times
daily
Placebo Lung
function*
Exercise
capacity*
HRQL
Sputum
analysis
COPE
15/
Netherlands/
2002
Parallel 6 months (follow up
at 3& 6 months)
244 4
months
FP 500 ug twice daily
& ipratropium
bromide 40 ug four
times daily
FP 500 ug twice
daily and
Ipratropium
Placebo and
Ipratropium
First and
second
exacerbations*
Rapid
recurrent
exacerbation*
HRQL*
Lung function
Exercise
tolerance
Use of
healthcare
facilities
Respiratory
symptoms
COSMIC
16/
Netherlands/
2005
Parallel 12 months (follow up
at weeks 0, 4, 11, 12,
16, 28, 40, 52, 64 &
66)
373 3
months
Combined salmeterol
50 ug & fluticasone
500 ug twice daily
Combined
salmeterol 50 ug &
fluticasone 500 ug
twice daily
Salmeterol
50 ug twice
daily
Lung
function*
Exacerbation
& use of
rescue
medication
Respiratory
symptoms
HRQL
*Primary outcome measures.
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Study Age Sex Baseline severity of
COPD
Duration of inhaled steroid use
prior to entry into trial
Mean baseline
FEV
1
Mean baseline number of
exacerbations in year preceding trial
WISP
14 > 40 Male &
female
Post-bronchodilator
FEV1 < 80% predicted
Minimum 6 months, mean 8
years
Withdrawn group:
1.40 L
Steroid group: 1.31
L
(post-
bronchodilator)
Withdrawn group: 1.86
Steroid group: 1.93
O’Brien et
al
17
40-
79
Male Details not provided Details not provided 1.61 L Details not provided
COPE
15 40-
75
Male &
female
Pre-bronchodilator FEV1
25-80% predicted
83% of patients had used for at
least 6 months
Withdrawn group:
1.69 L
Steroid group: 1.78
L
(post-
bronchodilator)
All patients: 1.3
COSMIC
16 40-
75
Male &
female
Pre-bronchodilator FEV1
30-70% predicted
Details not provided Withdrawn group:
49.0
Steroid group: 48.1
(pre-
bronchodilator %
predicted)
Details not provided, all patients had 2
or more requiring treatment
Table 3 The methodological quality of the trials
Type of bias Criteria WISP O’Brien et al COPE COSMIC
Selection Method used
to generate
randomisation
sequence?
’Patients were allocated with
minimisation to intervention
using the programme MINIM
v1.3’
’Randomisation was
performed by the
clinical pharmacist
who randomised an
odd number dice
roll to placebo and
an even number
dice roll to drug’
’Randomisation was
performed in blocks of six by
computer generated
allocation’
’A randomisation schedule
generated by the patient
allocation for clinical trials
(PACT) program’
Method used
to generate
allocation
concealment?
’Inhalers were given an
alphanumeric code to
conceal allocation’
Inadequate Unclear Unclear
Performance Double-
blinding?
’Study nurses and regular
clinicians were blind to
allocation throughout the
study’
’The subject and
pulmonary physician
were blinded to the
treatment regimen.
Placebo and drug
MDI canisters were
identical, and the
placebo mist was
flavoured to make
the treatments
indistinguishable’
’This study was a randomised,
double-blind parallel-group
single centre study...’
’the study medication was
packed in identical inhaler
devices to ensure both the
patient and investigator were
unaware of the allocated
treatment’
Attrition Loss of
patients
accounted for?
Steroid Placebo Unclear Steroid Placebo Steroid Placebo
Number
randomised
128 132 Number
randomised
123 121 Number
randomised
189 184
Number
analysed
128 132 Number
analysed
122(1
died)
120(1
died)
Number
analysed
unclear unclear
Detection Outcome
assessor blind
Unclear Unclear Unclear Unclear
Reporting Any evidence
of reporting
bias?
No No No No
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Page 5 of 10frequency or number of exacerbations. Two trials showed
a statistically significant decrease in the time to first
exacerbation. Effects on other outcomes are inconclusive.
These results are not inconsistent with a recent review in
which the authors suggest that the benefits of ICS in pre-
venting COPD exacerbations may be overstated [20].
Strengths and limitations
We conducted a robust systematic review. Nevertheless, we
did not assess publications in languages other than English
and, given the small number of studies identified, could not
assess publication bias. Limited data within the trial reports
meant that we were only able to conduct one meta-analysis.
Meta-analysis
There are reasons for being cautious about the one
meta-analysis we conducted and, in general, meta-ana-
lysing results from these types of trial. First, there are
differences in patient characteristics between trials, in
this case duration of use of ICS and exacerbation rate
prior to entry to the trial which may be related to a
patient’s dependency on inhaled steroids, and differences
in outcome definition, in this case definition of exacer-
bations (Table 5). The two trials conducted most
recently also showed less effect of withdrawal which
may reflect the increased efficacy of more recent medi-
cations which might have been taken alongside the
inhaled steroids, although the use of other medication is
not reported in detail in the trial reports. An additional
reason for being cautious about meta-analysis in trials
where medication is withdrawn relates to patient man-
agement during the trial, specifically in these trials, the
management of exacerbations severe enough to make it
unethical for patients to continue on the randomised
treatment (Table 4). The WISP study had the highest
number of patients discontinuing randomised treatment;
46% in the placebo group and 26% in the fluticasone
group. In this trial, a patient’s own doctor managed any
exacerbation according to usual guidelines. The decision
to stop the study inhaler and return to the usual (pre-
randomisation) inhaler was made by the patient and
doctor without a clearly defined protocol. The proce-
dure was similar in the COSMIC study. By contrast, in
the COPE study patients only returned to their usual
medication following an examination and decision by
one of the trial physicians. Thus, patients in WISP and
COSMIC may have had a lower threshold for accepting
changes in their normal level of symptoms than in the
C O P Es t u d ya n dm a yh a v el e f tt h er a n d o m i s e dt r e a t -
ment earlier, especially in the placebo group, resulting
in a smaller observed difference in outcome between
this group and the fluticasone group in these trials. It is
not possible to be prescriptive about a protocol for
managing severe exacerbations; different approaches
reflect the point of the trial on the pragmatic/explana-
tory spectrum, and trials at all points are useful in this
context. For example, COPE suggests that withdrawing
ICS results in an increase in the likelihood of an exacer-
bation but from WISP there is no indication that doing
so in a routine clinical setting with patients participating
Favours placebo             Favours ICS 
.405894  1  2.4637 
 % Weight 
 Odds ratio 
 (95% CI) 
 1.49 (0.90,2.46)  COPE   25.7
 0.94 (0.62,1.42)  COSMIC   48.2
 1.04 (0.60,1.80)  WISP   26.1
 1.11 (0.84,1.46)  Overall (95% CI) 
Figure 2 Meta-analysis of the odds ratio of patients experiencing at least one exacerbation.
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Page 6 of 10Table 4 Effect size (withdrawn compared with active treatment) 95% confidence intervals and denominators for study outcomes
Outcome
Study Whether
exacerbation or
not during study
period (odds ratio)
Time to first
exacerbation (mean (M)
or median (m))
Frequency of exacerbation
requiring course of
steroids or antibiotics(rate
ratio (rr) or hazard ratio
(hr))
Lung function(mean
difference in change
from baseline)
Total SGRQ score (mean
difference in change from
baseline)
Walking distance in 6
minutes (mean
difference in change
from baseline)
Borg exercise
tolerance test
(units)
COPE 1.5 (0.9 to 2.5)
(n = 242)
a
34.6 (M) (15.4 to 53.8)
(not clear)
1.5 (hr) (1.1 to 2.1)
(not clear)
-38 ml (-79.5 to 1.6)
(n = 242)
2.5 (0.4 to 4.6)
(not clear)
9.4 m (-4.5 to 23.2)
(n = 172)
-0.3 (-0.7 to 0.3)
(n = 173)
COSMIC 0.9 (0.6 to 1.4)
(n = 373)
b
Not measured 1.2 (rr) (0.9 to 1.5)
(n = 373)
-4.1% (-6.6 to -1.6)
(not clear)
0.9 (-.1.3 to 3.1)
(not clear)
Not measured Not measured
WISP 1.0 (0.6 to 1.8)
(n = 260)
b
19 (m) Not given
c 1.3 (rr) (1.0 to 1.6)
(n = 260)
-23 ml (-101.5 to 55.5)
(not clear)
-0.45 Unable to estimate Not measured Not measured
O’Brien Not measured Not measured Not measured -11.3% (-23.4 to 0.8) Not measured -32 ft (-771 to 707) Unable to
estimate
d
a all of these exacerbations were moderate - in this trial investigators did not measure exacerbations not requiring treatment
b these exacerbations were mild, moderate or severe
c median = 44 days in withdrawn group (CI 29-59) v. 63 (CI 53-74) days in steroid group, P = 0.05
d incorrect confidence interval given in publication.
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likely to result in a change in proportions exacerbating.
Reporting of individual trials
We recommend that authors make it clear in these trials
what other medication patients were likely to have been
taking during the trial period and whether there were
differences between intervention and control, particu-
larly in situations where the drug being withdrawn is
generally seen as an add-on to other medication, as in
the case of inhaled corticosteroids. In the COSMIC trial,
all patients were prescribed a long acting bronchodilator
as part of the trial. In the COPE trial, data on the use of
rescue b2 agonists during the study were collected but
n o tp r e s e n t e di nt h ep a p e r .I nW I S Pi ti sr e p o r t e dt h a t
those in the placebo group used a reliever inhaler more
frequently during the trial than those in the treatment
group. No information is given in the O’Brien trial
regarding other medications. Another factor that needs
to be clearly reported is the length of time patients have
been on inhaled corticosteroids prior to the start of the
trial as this may influence the effect of withdrawal; two
trials did not give any details of this.
The differences between the trials in the treatment of
those experiencing severe exacerbations highlight the
need for clear reporting in this area. Currently there is
no agreed classification of exacerbations [12]. Providing
a clear classification is useful to compare the severity of
exacerbations between the groups in a trial, but there
needs to be some flexibility in defining events likely to
Table 5 Summary of the way in which trials define and manage exacerbations
WISP O’Brien
et al
COPE COSMIC
Definition of exacerbation ’The presence of at least 2
consecutive days of increase in
any two ‘major’ symptoms
(increasing breathlessness, sputum
purulence and sputum
production” or increase in one
‘major’ and one ‘minor’ symptom
(wheeze, cough, cold/nasal
congestion, sore throat,
fever)’’Exacerbations were
classified as:
Unreported: fulfilled symptom
criteria on diary cards for a COPD
exacerbation but was not
managed with antibiotics or oral
steroids
Moderate: a COPD exacerbation
treated with a course of
antibiotics or oral steroids
Severe: a COPD exacerbation
treated with a course of
antibiotics or oral steroids
resulting in hospital admission’
None ’worsening of respiratory symptoms
that required treatment with a
short course of oral corticosteroids
or antibiotics as judged by the
study physician’
’Mild: if a patient on 2 or
more consecutive days used 3
or more extra inhalations of
salbutamol per 24 hours
above their RRV
Moderate: if a course of oral
steroids were indicated based
on a clinician’s judgement
Severe: if hospitalisation was
required’
Definition of very severe
exacerbations which would
warrant treatment with
medication other than the
randomised treatment
None None Rapid recurrent exacerbations:
‘twice an objective increase in
respiratory symptoms within a
three-month period, defined as
more than 20% or 300 ml decrease
in FEV1, compared with stable lung
function at randomisation, or 3
times a subjective increase of
respiratory symptoms in a 3-month
period as experienced by the
patient regardless of the criteria
mentioned previously’
None
Protocol for dealing with
exacerbations
’GP’s were advised to manage
exacerbations according to usual
guidance with antibiotics and/or
oral steroids. Decisions about
stopping study inhalers were
made by the general practitioner
and patient’
None ’If patients experienced any
worsening of symptoms, they were
advised to contact the COPE study
personnel by phone. They were
then invited to attend the hospital
within 12 hours for spirometry and
consultation by one of the study
physicians who decided to
continue the trial or to prescribe
500 mcg FP twice daily unblinded’
’Standardised course of
prednisolone 30 mg/day for
ten days accompanied by a
10 day course of antibiotics.’
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Page 8 of 10warrant a withdrawal from randomised treatment in
these trials. Nevertheless, it is important for authors to
report the method of managing exacerbations so that
those reading reports are able to interpret results.
A further issue that we became aware of in reviewing
these trials is the description of those who discontinue
randomised treatment. In the COSMIC trial these indi-
viduals were described as drop-outs, although they
appeared to provide outcome measures. We suggest that
these individuals would be better described as ‘disconti-
nuers’ and those who do not provide outcome data
described as drop outs from the trial. Using this termi-
nology, there were no drop outs in the COSMIC or
WISP studies, and only two (both deaths) in the COPE
study. There were 134 discontinuers (51%) in the WISP
study (56 ICS, 78 placebo), 80 (21%) in COSMIC (34
ICS, 46 placebo) and 32 (13%) in COPE (6 ICS, 26 pla-
cebo). Furthermore, taking a pragmatic approach, which
is necessary in these trials on ethical grounds, differ-
ences in discontinuation between groups are not of
paramount importance in assessing the effect of
withdrawal.
Analysis and interpretation of individual trials
How should the results of these trials be analysed and
how should these analyses be interpreted? Intention-to-
treat (ITT) is the recommended analysis for pragmatic
superiority randomised controlled trials [21]. Per proto-
col analyses were originally suggested as the preferred
way to analyse explanatory trials [22], but are now gen-
erally regarded as at best an adjunct to ITT analyses
because of the potential for selection bias [23]. Here we
exemplify this argument for trials where medication is
withdrawn.
In such trials, the ethical imperative to allow patients
to discontinue randomised treatment and the fact that
more in the placebo group usually do so, means that in
a per protocol analysis there are likely to be more
severely ill individuals in the group receiving ICSs. Thus
a per protocol analysis will often underestimate the
effect of the withdrawal of treatment on the target
population as a whole, and its usefulness in trials at the
explanatory end of the spectrum is diminished because
an underestimate of effect might lead to treatment being
withdrawn when in fact this withdrawal may be harmful.
Intention-to-treat analyses make more sense in these
trials, but should be interpreted in the context in which
the trial is being undertaken. Given the potential differ-
ences between the management of patients in different
trials, as illustrated in this paper, this interpretation may
be unique to the context, and comparisons between dif-
ferent trial results should be made with caution.
Whether there are more suitable analyses for trials in
which treatment is withdrawn is an important question.
For trials with binary outcomes, Graham Dunn devel-
oped a method of allowing for non-compliance while
effectively keeping all individuals in an analysis thus
overcoming one of the criticisms of per protocol ana-
lyses that the balance achieved by randomisation is bro-
ken [24]. To our knowledge, there are no publications
extending this method to survival analysis, particularly
when outcomes are repeated, or to trials in which medi-
cation is withdrawn. However, a more important ques-
tion than the overall effect of withdrawal of treatment
on the population may be the identification of patients
for whom withdrawal likely to be non-detrimental either
in the short or long term.
A further issue in relation to interpretation is the risk
of bias introduced by unblinding of patients who have
had an exacerbation severe enough to warrant a discon-
tinuation of randomised treatment. It seems likely that
t h e r ew i l lb em o r eo ft h e s ep a t i e n t si nt h ep l a c e b o
group and this may introduce performance bias.
Clinical implications
At the moment there are no national or international
guidelines advocating the withdrawal of inhaled corti-
costeroids in those with COPD. Our review does not
indicate that patients withdrawn from inhaled corticos-
teroids will, in general, have substantially worse out-
comes than those not withdrawn. Nevertheless, we
cannot advocate the withdrawal of inhaled corticoster-
oids in patients with COPD until further studies confirm
which subsets of COPD patients benefit from this treat-
ment and which subsets are at most risk of developing
side effects.
Conclusion
The withdrawal of ICS in patients with COPD may
cause exacerbations sooner with a smaller effect on the
number of exacerbations. Effects differ according to the
definition of outcome and setting and management of
patients within the trial. Clarity is needed in the report-
ing of these trials, particularly in defining exacerbations,
reporting the management of exacerbations severe
enough to warrant discontinuation of randomised treat-
ment, the description of individuals who discontinue,
and the collection and analysis of their outcomes. ITT
analyses are appropriate for these trials, but other meth-
ods of analysis could be explored including analyses
which attempt to identify those for whom discontinua-
tion results in little in the way of detrimental effects.
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